Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine.
about
Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (shuffling).Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma.Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer.Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88.Immunotherapeutic polyoma and human papilloma virus-like particles.Immunotherapy for polyomaviruses: opportunities and challenges.Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.Coadministration of the fungal immunomodulatory protein FIP-Fve and a tumour-associated antigen enhanced antitumour immunity.Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses.Development of chimeric candidate vaccine against HPV18: a proof of concept.Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy.Therapeutic vaccines for high-risk HPV-associated diseases.
P2860
Q34434903-FFD5594B-0FD3-471F-B229-0C81418E05C1Q34571825-2106B772-0DCC-4EEB-9F38-48E71A5432C5Q35155333-9F00E642-F1EE-4E2C-8606-DC9FCBE58F35Q35552591-517A96F1-4A8F-4E90-9870-F49FDD84CA13Q36622535-D4A500F3-4AF8-46F7-880D-086DEAB5AEF6Q36897382-80DA0F02-D8B0-4647-A3AF-CBE0DBA1DA16Q37568227-A62E002F-2206-4B5B-8E8D-971E1E7A5C05Q37773267-22D4B26B-15ED-4B0C-A110-CE1773FC5BA6Q38025665-2F455D62-143D-4D3D-AD6B-78C524549BDBQ39742082-0B48E278-DC8C-4A85-A143-E21D999E2672Q39796145-D2C68C2E-094D-4008-8012-0A96BA920655Q40762506-2FC35289-A423-4E60-8480-7BA0FF9EADFDQ41269236-BE26803F-50A8-4401-ABCB-726E6BE077E3Q44280889-1BB768CF-5828-4785-8325-8C93043C3DDEQ47255618-DB38D24D-24B6-43BE-A37A-90499F83FF2D
P2860
Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Chimeric virus-like particles ...... actic and therapeutic vaccine.
@ast
Chimeric virus-like particles ...... actic and therapeutic vaccine.
@en
type
label
Chimeric virus-like particles ...... actic and therapeutic vaccine.
@ast
Chimeric virus-like particles ...... actic and therapeutic vaccine.
@en
prefLabel
Chimeric virus-like particles ...... actic and therapeutic vaccine.
@ast
Chimeric virus-like particles ...... actic and therapeutic vaccine.
@en
P2093
P1476
Chimeric virus-like particles ...... actic and therapeutic vaccine.
@en
P2093
P304
P356
10.1016/S0188-0128(99)00026-3
P577
1999-07-01T00:00:00Z